Literature DB >> 15935398

Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.

Chiaki Isobe1, Takahiko Murata, Chigumi Sato, Yasuo Terayama.   

Abstract

We determined the concentrations of free homocysteine (HC) and total HC in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) or Parkinson's disease (PD) in order to elucidate whether HC is related to the pathogenesis of these neurodegenerative diseases. The concentration of free HC did not differ significantly from that of the normal controls, while the concentration of total HC was significantly higher in the AD and PD patients (+31% in AD,+31% in PD; p<0.05). These findings suggest that an increase of total HC concentration in the brain is commonly seen in patients with AD and PD, and this may be related to the pathogenesis of these two diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15935398     DOI: 10.1016/j.lfs.2005.02.014

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  26 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  In vivo 1 H MRS detection of cystathionine in human brain tumors.

Authors:  Francesca Branzoli; Dinesh K Deelchand; Marc Sanson; Stéphane Lehéricy; Małgorzata Marjańska
Journal:  Magn Reson Med       Date:  2019-05-26       Impact factor: 4.668

3.  Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

Authors:  Thomas Müller; Wilfried Kuhn
Journal:  Eur J Clin Pharmacol       Date:  2006-04-22       Impact factor: 2.953

4.  Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.

Authors:  L F Agnati; G Leo; S Genedani; L Piron; A Rivera; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-11-19       Impact factor: 3.575

5.  Increased transsulfuration mediates longevity and dietary restriction in Drosophila.

Authors:  Hadise Kabil; Omer Kabil; Ruma Banerjee; Lawrence G Harshman; Scott D Pletcher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 6.  Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease.

Authors:  Aracely Garcia-Garcia; Laura Zavala-Flores; Humberto Rodriguez-Rocha; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2012-05-03       Impact factor: 8.401

7.  Homocysteine, another risk factor for Alzheimer disease, impairs apolipoprotein E3 function.

Authors:  Hirohisa Minagawa; Atsushi Watanabe; Hiroyasu Akatsu; Kayo Adachi; Chigumi Ohtsuka; Yasuo Terayama; Takashi Hosono; Satoshi Takahashi; Hideaki Wakita; Cha-Gyun Jung; Hiroto Komano; Makoto Michikawa
Journal:  J Biol Chem       Date:  2010-10-01       Impact factor: 5.157

8.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

9.  One-carbon metabolism and Alzheimer's disease: focus on epigenetics.

Authors:  Fabio Coppedè
Journal:  Curr Genomics       Date:  2010-06       Impact factor: 2.236

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.